BioCentury | Jun 25, 2015
Distillery Techniques

Techniques: Mutations in nuclear factor of κ light polypeptide gene enhancer in B cells inhibitor ε (NFKBIE; IKBE) as a prognostic marker for chronic lymphocyti

Biomarkers NFKBIE IKBE Uppsala University BC Staff...
BioCentury | Oct 7, 2010
Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/ pathway Summary Licensing status Publication and contact information Cancer Acute lymphoblastic leukemia (ALL) IkB kinase (IKK) In vitro and mouse studies suggest that inhibiting IKK could help treat T...
BioCentury | May 13, 2010
Distillery Therapeutics

Indication: Inflammation

Indication Target/marker/ pathway Summary Licensing status Publication and contact information Inflammation Inflammation IkB kinase (IKK) In vitro and mouse studies suggest that vinpocetine could help treat inflammation. In a mouse model of lipopolysaccharide (LPS)- or...
BioCentury | Jun 4, 2009
Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Breast cancer NF-kB; IkB kinase-e (IKKe); cylindromatosis (turban tumor syndrome) (CYLD) In vitro and in vivo studies suggest that targeting IKKe...
BioCentury | Mar 26, 2009
Distillery Therapeutics

Indication: Inflammation

This week in therapeutics Indication Target/marker/ pathway Summary Licensing status Publication and contact information Inflammation Inflammatory disease IkB kinase (IKK) An SAR study characterized a series of oxazole, thiazole and imidazole tricycles as IKK inhibitors...
BioCentury | Oct 9, 2008
Distillery Therapeutics

This Week in Therapeutics

This week in therapeutics Indication Target/marker/ pathway Summary Licensing status Publication and contact information Endocrine disease Obesity IkB kinase-b (IKKb); NF-kB Studies in mice suggest that blocking IKKb and NF-kB interactions in the hypothalamus could...
BioCentury | Jun 26, 2008
Distillery Therapeutics

This Week in Therapeutics

This week in therapeutics Indication Target/ marker/pathway Summary Licensing status Publication and contact information Cancer Melanoma Kinase inhibitor of nuclear factor-kB-1 (KINK-1); IkB kinase-b (IKKb); NF-kB Studies in cell lines and mice suggest that KINK-1...
BioCentury | Jun 5, 2008
Distillery Therapeutics

This Week in Therapeutics

This week in therapeutics Indication Target/ marker/pathway Summary Licensing status Publication and contact information Various Chronic inflammatory disease; infectious disease IkB kinase-b (IKKb) Macrophage studies, both in vitro and in vivo, suggest that targeting IKKb...
BioCentury | Apr 24, 2008
Distillery Therapeutics

This Week in Therapeutics

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer IkB kinase (IKK); NF-kB; type 1 glucose transporter (GLUT3) A study in cell culture suggests that blocking or downregulating IKK...
BioCentury | Mar 24, 2008
Finance

Nomura's investments

Nomura's investments Nomura's investments Nomura Phase4 Ventures has invested in at least 25 biotechs since 1999. Usually Nomura's contribution for an initial investment will be some $15-$25 million of the round, although in subsequent rounds...
Items per page:
1 - 10 of 37